Overview
Riley Ennis is co-founder and chief product officer of Freenome, helping make Freenome’s vision of a cancer-free world a reality per the company’s official biography page. As CPO, Ennis heads clinical and commercial development of Freenome’s noninvasive tests for early cancer detection and treatment selection.
Freenome applies multiomics and machine learning to blood-based screening — a category where product leadership requires bridging laboratory science, clinical trial design, and commercial diagnostic launch timelines.
Role and company
As Co-Founder and Chief Product Officer, Ennis shapes Freenome’s product roadmap for blood-based multi-cancer screening from R&D through commercialization. Freenome’s team page positions Ennis at the intersection of biotechnology entrepreneurship and product strategy — reflecting dual competencies required in regulated diagnostic companies.
Ennis’s CPO role spans clinical study design inputs and commercial product definition — not solely engineering feature prioritization common in software-only health tech.
Background and career context
Ennis is a Thiel Fellow who developed a cancer vaccine and founded his first biotech company, Immudicon, while still in high school per Freenome biography. While earning his degree in molecular biology at Dartmouth, he co-authored several publications and worked as a visiting scientist with Novartis.
Ennis worked as an analyst at Morgan Stanley and an associate at Bridgewater, where he observed the positive impact of strong organizational culture firsthand per the cited biography.
Company-building or leadership context
Ennis’s prior biotech experience includes work at Foundation Medicine, Syros Pharmaceuticals, Adimab, and Emergent Biosolutions per Freenome biography — giving him exposure to diagnostic and therapeutic development cultures before co-founding Freenome. Thiel Fellowship and high-school Immudicon founding distinguish Ennis among healthcare AI founders with prodigy entrepreneur narratives.
Bridgewater associate experience informed Ennis’s emphasis on organizational culture in product-led diagnostic companies where clinical trial execution requires disciplined operations.
Public milestones
Freenome official biography documents Ennis’s Thiel Fellowship, Immudicon founding in high school, Dartmouth molecular biology degree with publications, Novartis visiting scientist role, and finance experience at Morgan Stanley and Bridgewater. Ennis is Co-Founder and Chief Product Officer on freenome.com reviewed July 10, 2026.
Freenome continues clinical development of blood-based screening tests per company our-company materials.
Why their work matters
Freenome under Ennis’s product leadership tests whether multi-cancer blood screening can achieve commercial adoption with rigorous clinical evidence — a category where prior GRAIL and Exact Sciences milestones set high validation bars. Ennis’s science-plus-finance background helps bridge laboratory R&D timelines and capital markets expectations.
For healthcare AI readers, Freenome is diagnostic multiomics AI — distinct from clinical workflow documentation but central to preventive health economics.
Sources and references
Primary sourcing: Freenome Riley Ennis biography page, reviewed July 10, 2026.
- Freenome — Riley Ennis CPO (freenome.com)
Education and prior roles from official Freenome biography only.
Ennis’s Bridgewater associate experience observing strong organizational culture per Freenome biography informs product development discipline required for multi-year blood-based cancer screening clinical programs. Prior roles at Foundation Medicine, Syros Pharmaceuticals, Adimab, and Emergent Biosolutions give Ennis exposure to diagnostic and therapeutic cultures Freenome’s CPO role must bridge when translating multiomics R&D into commercial screening products.
Freenome biography documents Ennis as Thiel Fellow, high-school Immudicon founder, Dartmouth molecular biology graduate with publications, Novartis visiting scientist, and Morgan Stanley analyst — a career arc combining prodigy biotech credentials with finance operations experience uncommon among healthcare product leaders.